Cargando…

Makulopathie bei Sichelzellerkrankung

BACKGROUND: Sickle cell disease (SCD) is a hereditary hemoglobinopathy, which leads to microcirculatory disturbances of various organ systems through recurrent vaso-occlusive episodes, with a possibly fatal outcome. Sickle cell retinopathy (SCR) is the best described ocular manifestation of SCD. Irr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachmeier, Isabel, Blecha, Christiane, Föll, Jürgen, Wolff, Daniel, Jägle, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492597/
https://www.ncbi.nlm.nih.gov/pubmed/33502544
http://dx.doi.org/10.1007/s00347-020-01319-8
_version_ 1784578947420258304
author Bachmeier, Isabel
Blecha, Christiane
Föll, Jürgen
Wolff, Daniel
Jägle, Herbert
author_facet Bachmeier, Isabel
Blecha, Christiane
Föll, Jürgen
Wolff, Daniel
Jägle, Herbert
author_sort Bachmeier, Isabel
collection PubMed
description BACKGROUND: Sickle cell disease (SCD) is a hereditary hemoglobinopathy, which leads to microcirculatory disturbances of various organ systems through recurrent vaso-occlusive episodes, with a possibly fatal outcome. Sickle cell retinopathy (SCR) is the best described ocular manifestation of SCD. Irrespective of the presence of peripheral SCR, sickle cell maculopathy (SCM) can occur early in the course of the disease. METHODS: Review of the international and German literature on ocular involvement in SCD with a focus on SCR and SCM and an overview of current systemic therapeutic approaches in SCD on the occasion of the presentation of two patients with HbSS SCD. RESULTS AND CONCLUSION: In contrast to SCR, SCM with temporal thinning of the inner retinal layers has only been increasingly described in the literature in the last 5 years, with the advent of SD-OCT and OCTA. Irrespective of the presence of SCR, as many as about half of the patients may develop SCM early in the course of the disease. As a result of progress in systemic therapeutic options and due to migration, the clinical picture will occur more often also in Germany. By knowing about this complication of SCD an early diagnosis can be made and unnecessary diagnostics can be avoided.
format Online
Article
Text
id pubmed-8492597
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-84925972021-10-15 Makulopathie bei Sichelzellerkrankung Bachmeier, Isabel Blecha, Christiane Föll, Jürgen Wolff, Daniel Jägle, Herbert Ophthalmologe Übersichten BACKGROUND: Sickle cell disease (SCD) is a hereditary hemoglobinopathy, which leads to microcirculatory disturbances of various organ systems through recurrent vaso-occlusive episodes, with a possibly fatal outcome. Sickle cell retinopathy (SCR) is the best described ocular manifestation of SCD. Irrespective of the presence of peripheral SCR, sickle cell maculopathy (SCM) can occur early in the course of the disease. METHODS: Review of the international and German literature on ocular involvement in SCD with a focus on SCR and SCM and an overview of current systemic therapeutic approaches in SCD on the occasion of the presentation of two patients with HbSS SCD. RESULTS AND CONCLUSION: In contrast to SCR, SCM with temporal thinning of the inner retinal layers has only been increasingly described in the literature in the last 5 years, with the advent of SD-OCT and OCTA. Irrespective of the presence of SCR, as many as about half of the patients may develop SCM early in the course of the disease. As a result of progress in systemic therapeutic options and due to migration, the clinical picture will occur more often also in Germany. By knowing about this complication of SCD an early diagnosis can be made and unnecessary diagnostics can be avoided. Springer Medizin 2021-01-27 2021 /pmc/articles/PMC8492597/ /pubmed/33502544 http://dx.doi.org/10.1007/s00347-020-01319-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Übersichten
Bachmeier, Isabel
Blecha, Christiane
Föll, Jürgen
Wolff, Daniel
Jägle, Herbert
Makulopathie bei Sichelzellerkrankung
title Makulopathie bei Sichelzellerkrankung
title_full Makulopathie bei Sichelzellerkrankung
title_fullStr Makulopathie bei Sichelzellerkrankung
title_full_unstemmed Makulopathie bei Sichelzellerkrankung
title_short Makulopathie bei Sichelzellerkrankung
title_sort makulopathie bei sichelzellerkrankung
topic Übersichten
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492597/
https://www.ncbi.nlm.nih.gov/pubmed/33502544
http://dx.doi.org/10.1007/s00347-020-01319-8
work_keys_str_mv AT bachmeierisabel makulopathiebeisichelzellerkrankung
AT blechachristiane makulopathiebeisichelzellerkrankung
AT folljurgen makulopathiebeisichelzellerkrankung
AT wolffdaniel makulopathiebeisichelzellerkrankung
AT jagleherbert makulopathiebeisichelzellerkrankung